The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry

Cancer
R A StephensonR L Dibble

Abstract

In the 1980s, prostate specific antigen (PSA) came into wide use as a prostate carcinoma screening and detection method in the United States. Following the introduction of PSA, the age-adjusted incidence of prostate carcinoma reported by the Surveillance, Epidemiology, and End Results (SEER) program in the United States rose rapidly (from 84.4/100,000 in 1984 to 163/100,000 in 1991). When an increase in incidence is observed following the introduction of a screening method, a subsequent decrease in incidence may be expected as prevalent cases are removed from the population (a cull effect). Incidence rates may also fall due to factors such as decreased intensity of screening. The Utah Cancer Registry data were examined for a decrease in prostate cancer incidence. We tracked age-adjusted prostate carcinoma incidence trends from the population-based Utah Cancer Registry and compared them with rates from the SEER national registry. A rapid and highly correlated rise in prostate carcinoma incidence has been observed in both SEER and Utah incidence rates between 1988 and 1991, the last year for which SEER data are available. In 1992, Utah incidence rates peaked at 236.2 per 100,000. In 1993 and 1994, Utah incidence rates fell to 195...Continue Reading

References

Apr 15, 1978·International Journal of Cancer. Journal International Du Cancer·G JohannessonN Day
Mar 1, 1992·The Journal of Urology·M K BrawerP H Lange
Mar 1, 1992·Human Pathology·P T ScardinoM A Hudson
Jul 1, 1992·CA: a Cancer Journal for Clinicians·P J LittrupC Mettlin
Apr 22, 1992·JAMA : the Journal of the American Medical Association·J E JohanssonU B Krusemo
Apr 1, 1992·American Journal of Obstetrics and Gynecology·J L BenedetJ P Matisic
Jul 30, 1992·The New England Journal of Medicine·J R HarrisW Willett
Jan 1, 1992·CA: a Cancer Journal for Clinicians·C C BoringT Tong
Jul 1, 1982·CA: a Cancer Journal for Clinicians·L H Baker
Nov 1, 1994·The Journal of Urology·D S Smith, W J Catalona
Jan 1, 1995·CA: a Cancer Journal for Clinicians·P A WingoS Bolden
Jan 25, 1995·JAMA : the Journal of the American Medical Association·P H GannM J Stampfer
Feb 15, 1995·JAMA : the Journal of the American Medical Association·A L PotoskyB S Kramer
Aug 25, 1993·JAMA : the Journal of the American Medical Association·W J CatalonaJ W Basler
Jan 1, 1993·European Urology·G S Gerber, G W Chodak
Nov 1, 1993·Annals of Internal Medicine·B S KramerJ K Gohagan
Jan 29, 1994·Lancet·G L Lu-Yao, E R Greenberg
Nov 1, 1994·The Journal of Urology·J R BeckB J Miles
Dec 1, 1994·Urology·R M Benoit, M J Naslund
Nov 15, 1993·Annals of Internal Medicine·S Bilgrami, B Greenberg
Jan 27, 1994·The New England Journal of Medicine·G W ChodakJ Warner
Jan 1, 1994·CA: a Cancer Journal for Clinicians·C C BoringS Montgomery
Nov 15, 1993·Annals of Internal Medicine·A Spital
Jan 6, 1993·JAMA : the Journal of the American Medical Association·G S GerberG W Chodak
Jan 1, 1993·CA: a Cancer Journal for Clinicians·B A MillerB F Hankey
Jan 1, 1993·CA: a Cancer Journal for Clinicians·C C BoringT Tong
Jun 19, 1993·International Journal of Cancer. Journal International Du Cancer·K Sigurdsson
Nov 29, 2007·Journal of the National Cancer Institute·Liz Savage

❮ Previous
Next ❯

Citations

May 17, 2007·Prostate Cancer and Prostatic Diseases·A B JaniP A S Johnstone
Nov 6, 1998·Clinical Chemistry and Laboratory Medicine : CCLM·R Daher, M Beaini
Jan 1, 1987·Scandinavian Journal of Thoracic and Cardiovascular Surgery·S LarssonV Lepore
Sep 11, 2007·European Urology·Richard J Bryant, Freddie C Hamdy
Apr 5, 2000·Current Problems in Cancer·G C Morton
Oct 1, 1974·American Journal of Surgery·C R SmartL R Cowan
Dec 1, 1977·Preventive Medicine·J W Gardner, J L Lyon
Feb 15, 2001·The Journal of Urology·F D GillilandC R Key
Jan 5, 2002·International Journal of Cancer. Journal International Du Cancer·Harry J de KoningUNKNOWN International Prostate Cancer Screening Trials Evaluation Group
Nov 1, 2000·The Prostate. Supplement·F H Schröder
Jan 5, 2000·BJU International·J L BurtonJ B Anderson
Sep 23, 2003·The Journal of Urology·Filippos I KondylisPaul F Schellhammer
May 11, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M R Safarinejad
Oct 14, 2006·Current Opinion in Urology·J E Damber
Nov 29, 2002·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·D LousberghG Molenberghs
Mar 7, 2007·Annals of Saudi Medicine·H A Mosli
Oct 23, 1997·The Journal of Urology·J E FowlerJ M Kolski
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F M JhaveriH S Levin
Sep 14, 2019·Nursing Science Quarterly·Senay Karadag Arli, Ayse Berivan Bakan
Jul 15, 2018·Virchows Archiv : an International Journal of Pathology·Catarina FerreiraRui Henrique
Aug 8, 1998·The Medical Journal of Australia·T J ThrelfallI L Rouse
Jul 31, 2004·Urologic Oncology·Ithaar H DerweeshEric A Klein

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.